3
|
Loibl S, Untch M, Denkert C, Huober J, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kümmel S, Rautenberg B, Fasching PA, Rhiem K, Burchardi N, Schneeweiss A. Abstract P6-15-01: Withdrawn. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p6-15-01] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
This abstract was withdrawn by the authors.
Collapse
Affiliation(s)
- S Loibl
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - M Untch
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - C Denkert
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - J Huober
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - JU Blohmer
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - E-M Grischke
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - J Furlanetto
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - H Tesch
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - C Hanusch
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - M Rezai
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - C Jackisch
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - WD Schmitt
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - G von Minckwitz
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - J Thomalla
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - S Kümmel
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - B Rautenberg
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - PA Fasching
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - K Rhiem
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - N Burchardi
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| | - A Schneeweiss
- German Breast Group; Centrum für Hämatologie und Onkologie Bethanien Frankfurt; HELIOS Klinikum Berlin Buch; Universitätsfrauenklinik Ulm; Brustzentrum Charité; Universitätsfrauenklinik Tübingen; Klinikum zum Roten Kreuz München; Medical Center, Luisenkrankenhaus; Sana-Clinic, Offenbach; Praxisklinik für Hämatologie und Onkologie, Koblenz; Brustzentrum, Kliniken Essen-Mitte; Universitätsklinikum Freiburg; Brustzentrum Universitätsklinikum Erlangen; Uniklinik Köln; Charité University Hospital Berlin; National Center for Tumor Diseases (NCT), Heidelberg
| |
Collapse
|
4
|
Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Schmidt M, Klare P, Rezai M, Rautenberg B, Klutinus N, Rhein U, Mousa K, Ricardo-Vitorino S, von Minckwitz G, Bliss J. Abstract GS3-03: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial). Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-gs3-03] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
Inhibition of COX-2 has been shown to attenuate the metastatic process in pre-clinical models of human breast cancer (BC). The primary aim of this study was to assess the effect of 2 years adjuvant therapy with the COX-2 inhibitor celecoxib compared with placebo in HER2-ve primary BC patients.
Patients & Methods
Patients were randomised in a 2:1 ratio to receive celecoxib 400mg once daily or placebo for 2 years. Patients had to have completely resected BC with prior local and systemic adjuvant treatment according to local practice. Concurrent radiotherapy was permitted and hormone receptor +ve patients received endocrine therapy according to local practice. Patients with HER2+ or node negative, T1 and grade 1 disease were excluded. Median age of patients was 55 years (IQR: 49-63). 50% of patients had tumours >2cm; 42% were grade 3; 48% had node +ve disease. According to local assessment 73% were ER/PgR +ve. Primary endpoint was Disease Free Survival (DFS); defined as time from randomisation to date of first event, with events contributing to analysis defined as recurrence (distant/local), new primary BC (ipsilateral/contralateral) and death. Secondary endpoints included Overall Survival (OS), toxicity, cardiovascular mortality and incidence of second primaries. Subgroup analysis by hormone receptor status was pre-planned. Survival endpoints are analysed using Cox-proportional hazards and log-rank tests; restricted mean survival is used where proportional hazards do not hold.
Results
Between January 2007 and November 2012, 2639 patients were randomised (1763 celecoxib; 876 placebo) from 181 centres across the UK and Germany. At 13th April 2017, median follow up was 60 months (IQR: 48-72) with 428 DFS events reported. Unadjusted survival analysis results are presented below, with hazard ratio<1 favouring celecoxib:
5 year survival estimate (95% CI)Hazard ratio (95% CI)p-valueDFS (all patients) Celecoxib83% (81, 85)1.02 (0.83 – 1.24)0.88Placebo83% (80, 86)1- DFS within ER+ Celecoxib87% (85, 89)0.89 (0.69 – 1.16)0.40Placebo86% (83, 89)1- DFS within ER- Celecoxib72% (68, 76)1.17 (0.85 – 1.61)0.33Placebo75% (69, 80)1- OS (all patients) Celecoxib90% (88, 91)0.97 (0.75 – 1.25)0.81Placebo90% (88, 92)1-
The interaction between ER status and treatment was not significant; p=0.36.
In the celecoxib and placebo groups there were 17 and 8 deaths respectively in patients who had not relapsed. These were due to cardiac (n=3; 2) and other (n=14; 6) in the celecoxib and placebo groups respectively; none were GI related. In total 304 serious adverse events were observed in 265 patients (186/1763 celecoxib; 79/876 placebo). In the celecoxib and placebo groups respectively these were related to cardiac (n=12; 7), GI (n=9; 2) and other (n=193; 81). Work is ongoing to determine whether a subset of ER+ patients whose primary tumours show the characteristics of a COX-2 signature receive greater benefit from celecoxib.
Conclusions
There is no benefit of celecoxib in the ITT population. Further exploratory studies focussing on the ER+ subpopulation are ongoing. Celecoxib treatment is not associated with significant toxicity when compared to placebo in this population of BC patients.
Citation Format: Coombes RC, Tovey H, Kilburn L, Mansi J, Palmieri C, Bartlett J, Hicks J, Makris A, Evans A, Loibl S, Denkert C, Murray E, Grieve R, Coleman R, Schmidt M, Klare P, Rezai M, Rautenberg B, Klutinus N, Rhein U, Mousa K, Ricardo-Vitorino S, von Minckwitz G, Bliss J. A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients (REACT – Randomised EuropeAn celecoxib trial) [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr GS3-03.
Collapse
Affiliation(s)
- RC Coombes
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - H Tovey
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - L Kilburn
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - J Mansi
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - C Palmieri
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - J Bartlett
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - J Hicks
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - A Makris
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - A Evans
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - S Loibl
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - C Denkert
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - E Murray
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - R Grieve
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - R Coleman
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - M Schmidt
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - P Klare
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - M Rezai
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - B Rautenberg
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - N Klutinus
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - U Rhein
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - K Mousa
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - S Ricardo-Vitorino
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - G von Minckwitz
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| | - J Bliss
- Imperial College London, UK; Institute of Cancer Research - Clinical Trials and Statistics Unit, UK; Guys' & St Thomas' NHS Foundation Trust and Biomedical Research Centre, King's College London, UK; University of Liverpool and Clatterbridge Cancer Centre, UK; Ontario Institute for Cancer Research, Toronto, Canada; NHS Lanarkshire, UK; Mount Vernon Cancer Centre, UK; Poole Hospital NHS Foundation Trust, UK; German Breast Group, Neu-Isenburg, Germany; Charité University Hospital and German Cancer Consortium (DKTK), Berlin, Germany; United Lincolnshire Hospitals NHS Foundation Trust, UK; University Hospitals Coventry and Warwickshire NHS Trust, UK; University of Sheffield. Sheffield, UK; Praxisklinik Krebsheilkunde, Berlin, Germany; Luisenkrankenhaus Düsseldorf, Germany; Universitätsklinikum Freiburg, Germany; Klinikum Pforzheim GmbH, Germany; SRH Zentralklinikum Suhl GmbH, Germany; Universitatsmedizin Mainz, Germany
| |
Collapse
|